Our Pipeline
We have made considerable progress with our branded and generic product development activities. Focusing on our proprietary drug delivery technology expertise and core therapeutic categories, we continue to review strategic additions to our branded and generic product pipelines.
Watson Brands Product Pipeline Status
| Branded Product | Disease/Market | Alliance | Status |
|---|---|---|---|
| RAPAFLO TM | Benign-Prostatic Hyperplasia/Urology | Kissei | Approved |
| Oxybutynin Gel | Overactive Bladder/Urology | - | Submitted |
| TRELSTAR® 6-month formulation | Advanced Prostate Cancer/Urology | Debiopharm | Submitted |
| URACYST® | Interstitial cystitis | Stellar | Phase 2 |
Watson Generics Product Pipeline Status
| Pending ANDA's |
|---|
| ~60 |
